Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Dura to launch second Allergan product

June 20, 2000

Alcon discovers utility of glutamate antagonists for retinal disorders

June 9, 2000

Allergan and Xoma expand rBPI ophthalmic program

June 6, 2000

Visudyne therapy receives Canadian approval for treatment of wet AMD

June 2, 2000

Angiotech signs license agreement with Alcon for delivery of paclitaxel

May 30, 2000

Early use of PDT with verteporfin in age-related macular degeneration

May 24, 2000

New agents for cataracts designed by Sankyo

May 22, 2000

Squalamine demonstrates preclinical activity in retinopathy

May 19, 2000

Ciba Vision and QLT expand strategic alliance for developing new treatments for eye diseases

May 16, 2000

Special access program approved for Visudyne in Canada

May 11, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.